196 related articles for article (PubMed ID: 27436020)
1. Advanced non small cell lung cancer: response to microwave ablation and EGFR Status.
Wei Z; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y
Eur Radiol; 2017 Apr; 27(4):1685-1694. PubMed ID: 27436020
[TBL] [Abstract][Full Text] [Related]
2. Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Wei Z; Yang X; Ye X; Feng Q; Xu Y; Zhang L; Sun W; Dong Y; Meng Q; Li T; Wang C; Li G; Zhang K; Li P; Bi J; Xue G; Sun Y; Sheng L; Liu B; Yu G; Ren H; Wang J; Sun L; Chen S; Geng D; Zhang B; Xu X; Zhang L; Sun D; Xu X; Diao C; Huang G; Li W; Han X; Wang J; Meng M; Ni Y; Zheng A; Fan W; Li Y; Li F; Fan H; Zou Z; Li Q; Tian H
Eur Radiol; 2020 May; 30(5):2692-2702. PubMed ID: 32020400
[TBL] [Abstract][Full Text] [Related]
3. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study.
Ni Y; Bi J; Ye X; Fan W; Yu G; Yang X; Huang G; Li W; Wang J; Han X; Ni X; Wei Z; Han M; Zheng A; Meng M; Xue G; Zhang L; Wan C
Medicine (Baltimore); 2016 Jun; 95(25):e3998. PubMed ID: 27336903
[TBL] [Abstract][Full Text] [Related]
4. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
[TBL] [Abstract][Full Text] [Related]
5. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone.
Wei Z; Ye X; Yang X; Huang G; Li W; Wang J; Han X
Med Oncol; 2015 Feb; 32(2):464. PubMed ID: 25572816
[TBL] [Abstract][Full Text] [Related]
6. Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Li X; Qi H; Qing G; Song Z; Xie L; Cao F; Chen X; Fan W
Thorac Cancer; 2018 Aug; 9(8):1012-1017. PubMed ID: 29924498
[TBL] [Abstract][Full Text] [Related]
7. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
9. The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
Furuya N; Ito K; Sakaguchi T; Hida N; Kakinuma K; Morikawa K; Inoue T; Komase Y; Hataji O; Mineshita M
Oncology; 2020; 98(9):661-668. PubMed ID: 32464632
[TBL] [Abstract][Full Text] [Related]
10. Computed tomography-guided microwave ablation for the treatment of non-small cell lung cancer patients with and without adjacent lobe invasion: A comparative study.
Xu S; Bie ZX; Li YM; Li B; Guo RQ; Li XG
Thorac Cancer; 2021 Oct; 12(20):2780-2788. PubMed ID: 34427998
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
[TBL] [Abstract][Full Text] [Related]
12. Microwave ablation combined with chemotherapy improved progression free survival of IV stage lung adenocarcinoma patients compared with chemotherapy alone.
Li C; Wang J; Shao JB; Zhu LM; Sun ZG; Zhang N
Thorac Cancer; 2019 Jul; 10(7):1628-1635. PubMed ID: 31243894
[TBL] [Abstract][Full Text] [Related]
13. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy.
Wei Z; Zhan X; Fan L; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y; Li Q
Int J Hyperthermia; 2018; 35(1):591-598. PubMed ID: 30307348
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
[TBL] [Abstract][Full Text] [Related]
16. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
Wu TH; Hsiue EH; Lee JH; Lin CC; Liao WY; Ho CC; Shih JY; Yu CJ; Yang JC
Clin Lung Cancer; 2018 May; 19(3):e361-e372. PubMed ID: 29477365
[TBL] [Abstract][Full Text] [Related]
17. Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program.
Hong SH; An HJ; Kim K; Lee SS; Lee YG; Yuh YJ; Park IC; Chae YS; Jang TW; Kang JH
Oncology; 2019; 96(1):51-58. PubMed ID: 30368503
[TBL] [Abstract][Full Text] [Related]
18. Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer.
Wei Z; Yang X; Ye X; Huang G; Li W; Han X; Wang J; Meng M; Ni Y; Zou Z; Wen Q
J Cancer Res Ther; 2019; 15(7):1629-1634. PubMed ID: 31939448
[TBL] [Abstract][Full Text] [Related]
19. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Choi YW; Jeon SY; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Koh YW; Han JH; Sheen SS
Am J Clin Oncol; 2018 Apr; 41(4):385-390. PubMed ID: 26967328
[TBL] [Abstract][Full Text] [Related]
20. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
